Approval has been granted by the Medicines and Healthcare products Regulatory Agency (MHRA) for an adapted Pfizer/BioNTech Covid-19 vaccine that targets the Omicron XBB 1.5 subvariant. The new version of Comirnaty was found to meet the UK regulator’s standards of safety, quality and effectiveness and has been approved for use in individuals from six months […]